Recent research into retatrutide peptide highlight notable possibility for managing weight and type 2 disease. The compound, a dual activator of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, looks to offer improved weight reduction and blood sugar regulation compared existing therapies. Ongoing patient studies are requir